<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190730044386N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-12-12</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of home care on  quality of life, re-admission and HbA1C of patients with diabetes</public_title>
      <acronym></acronym>
      <scientific_title>The effect of home care on glycosylated hemoglobin, quality of life, and readmission of patients with type 2 diabetes who have undergone surgery and are being discharged from selected training centers</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-07-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/42993</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research, Randomization description: Random allocation by blocking method will be done as follows:
The researcher will divide the total sample size into smaller groups (groups of four) called blocks, considering that with a sample size of 70  and a quadruple block, an integer is not obtained, so we consider the number 72 and as a result we will have eighteen blocks. . The situations of placing people (four people) inside each block can be imagined and documented from the total number of samples from the intervention and control group
{ACAC, ACCA, CCAA, CAAC, AACC, CACA )then   assign a number to each of these blocks .ACAC = 1, ACCA = 2, CCAA = 3CAAC = 4, AACC = 5, CACA = 6 )) We write the numbers on the balls of the same color and size and put them in the bag, and  
The three-year-old then pulls a ball out of the bag and, after recording the number on the ball, returns it to the bag and pulls out the next ball. In this way, during the sampling, according to the order of the blocks and the number taken out of the bag, sampling will be done. It is necessary to explain that the previous block must be completed to complete the next block, Blinding description: In patient blinding, the researcher will explain the purpose of the study to both groups equally before randomly allocated the samples. Consent to participate in the study will be obtained from each participant in the study. Quality of life questionnaire for each of patients  will be completed and a blood sample will be taken for glycosylated hemoglobin. Then, according to the block number (in which the four samples should be placed)patients will be randomly placed in intervention or control groups.
Because sampling will be done on different days and in the morning and evening shifts, patients in the control and intervention groups will not be able to communicate with each other.
In this study, blindness will also be performed for the statistical analyst. For this purpose, the letters A and B will be used to enter the data of the intervention and control group, and the analyst will not be aware of which letter belongs to which group under study.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Diabetes Mellitus.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Home careInterventions in the test group include the following.A working team will be formed consisting of a nurse with 14 years of clinical experience (master's degree student in nursing) and her supervising professors (a PhD in nursing and an endocrinologist) a general surgeon and  a dietitian.1- Quality of life questionnaire and background characteristics will be completed by patients at the beginning of the study2. Blood samples will be taken from patients to perform glycosylated hemoglobin test3- The first home visit will be done in the first 24 hours after discharge to determine and prioritize the patient's educational, care, treatment and support needs.4- Planning to cover the prioritized needs will be done in a meeting with other team members.5- The nurse will have scheduled visits to the patients' homes for 3 months to perform educational and care interventions, including changing the dressing , measuring blood sugar and teaching self management behaviors.The duration of home visits is estimated at least three hours per week in the first month, and in the second and third months,depending on the patient's needs, the frequency and duration of home care will vary.6- In addition to the scheduled visits, the nurse (researcher) telephone number will be provided to the family, who will contact the nurse in case of emergency and, if necessary, an additional home care session will be planned and performed.8-The medical needs of the patient will be covered by the team doctor in two ways. a- The nurse, in coordination with the doctor, will collect the necessary information in the patient's home and transfer it to the doctor.The doctor will then make the necessary treatment recommendations to the nurse based on the information received, and the nurse will follow the doctor's orders at home.B- If necessary, the doctor will personally visit the patient at home.8. The patient's nutrition pattern will be evaluated and information will be provided to the team dietitian.dietitian's recommendations based on the patient's needs will be taught to the patient and family at the nurse's next visit.13. The readmission questionnaire will be completed by the nurse each time the patient is readmitted for three months.14- At the end of the third month, a blood sample for HbA1C will be sent to the laboratory again.At the end of the third month, patients will complete the quality of life questionnaire again. Intervention 2: Control group:1- Quality of life questionnaire and background characteristics will be completed by patients at the beginning of the study2. Blood samples will be taken from patients to perform glycosylated hemoglobin test.3-Patients will be informed that they will be referred three months later to complete the Quality of Life Questionnaire and take a blood sample for HbA1C .4-.At the beginning of the study, the readmission questionnaire will be provided to patients. They will be taught how to complete the questionnaire and they will be asked to complete the questionnaire each time they are readmitted for three months.5- The nurse's phone number is provided to the patients so that they can contact them if they have any questions about completing the readmission questionnaire.6- The nurse will make a monthly phone call to the patients to remind them about completing the readmission questionnaire and that they will be referred to them by the end of the third month to test for glycosylated hemoglobin and complete the quality of life questionnaire. 7- Patients in the control group will not receive any care and treatment from the research team during the study period.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Confidentiality of participants' information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Parvaneh Abazari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Fourth Floor, No 6, 18th Alley, Friborg Street</address>
        <city>Esfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8168783546</zip>
        <telephone>+98 31 3668 9207</telephone>
        <email>abazari@nm.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Parvaneh Abazari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Fourth Floor, No 6,18th Alley, Friborg Street</address>
        <city>Esfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8763453565</zip>
        <telephone>0098317927543</telephone>
        <email>abazari@nm.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients living in the geographical area of Isfahan
Persian language
Able to communicate verbally
type2 diabetes
Consent to participate in research
inpatient in surgical wards with discharge order
Consent the family to participate in the research
at least 45 years old</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E11</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Type 2 diabetes mellitus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Home careInterventions in the test group include the following.A working team will be formed consisting of a nurse with 14 years of clinical experience (master's degree student in nursing) and her supervising professors (a PhD in nursing and an endocrinologist) a general surgeon and  a dietitian.1- Quality of life questionnaire and background characteristics will be completed by patients at the beginning of the study2. Blood samples will be taken from patients to perform glycosylated hemoglobin test3- The first home visit will be done in the first 24 hours after discharge to determine and prioritize the patient's educational, care, treatment and support needs.4- Planning to cover the prioritized needs will be done in a meeting with other team members.5- The nurse will have scheduled visits to the patients' homes for 3 months to perform educational and care interventions, including changing the dressing , measuring blood sugar and teaching self management behaviors.The duration of home visits is estimated at least three hours per week in the first month, and in the second and third months,depending on the patient's needs, the frequency and duration of home care will vary.6- In addition to the scheduled visits, the nurse (researcher) telephone number will be provided to the family, who will contact the nurse in case of emergency and, if necessary, an additional home care session will be planned and performed.8-The medical needs of the patient will be covered by the team doctor in two ways. a- The nurse, in coordination with the doctor, will collect the necessary information in the patient's home and transfer it to the doctor.The doctor will then make the necessary treatment recommendations to the nurse based on the information received, and the nurse will follow the doctor's orders at home.B- If necessary, the doctor will personally visit the patient at home.8. The patient's nutrition pattern will be evaluated and information will be provided to the team dietitian.dietitian's recommendations based on the patient's needs will be taught to the patient and family at the nurse's next visit.13. The readmission questionnaire will be completed by the nurse each time the patient is readmitted for three months.14- At the end of the third month, a blood sample for HbA1C will be sent to the laboratory again.At the end of the third month, patients will complete the quality of life questionnaire again.</i_keyword>
      <i_keyword>Control group:1- Quality of life questionnaire and background characteristics will be completed by patients at the beginning of the study2. Blood samples will be taken from patients to perform glycosylated hemoglobin test.3-Patients will be informed that they will be referred three months later to complete the Quality of Life Questionnaire and take a blood sample for HbA1C .4-.At the beginning of the study, the readmission questionnaire will be provided to patients. They will be taught how to complete the questionnaire and they will be asked to complete the questionnaire each time they are readmitted for three months.5- The nurse's phone number is provided to the patients so that they can contact them if they have any questions about completing the readmission questionnaire.6- The nurse will make a monthly phone call to the patients to remind them about completing the readmission questionnaire and that they will be referred to them by the end of the third month to test for glycosylated hemoglobin and complete the quality of life questionnaire. 7- Patients in the control group will not receive any care and treatment from the research team during the study period.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>HbA1C. Timepoint: At the beginning of the study and 3 months later. Method of measurement: Chromatography.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Quality of life. Timepoint: At the beginning of the study and three months later. Method of measurement: Questionnaire.</sec_outcome>
      <sec_outcome>Readmission. Timepoint: At the beginning of the study and three months later. Method of measurement: Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-07-20</approval_date>
        <contact_name>Ethics committee of Esfahan University of Medical Sciences</contact_name>
        <contact_address>Fourth Floor,No 6,18th Alley,Friborg Street Esfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
